文献速递血脂与心血管预防冠心病

心脏代谢多病共存与种族对COVID-19患者心血管/肾脏并发症的影响

Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19.
PubMed 文献 · Heart · 2022-07-13

基于英国302家医疗机构65 624例COVID-19住院患者的前瞻性多中心队列研究,探讨基线心脏代谢疾病、多病共存及种族与院内心血管并发症和死亡的关系。结果显示68.0%患者至少有一种心脏代谢疾病,38.0%发生心血管/肾脏并发症或死亡;多病共存数量与并发症风险呈阶梯式升高,南亚和黑人种族风险更高。

要点

  • COVID-19住院患者中68.0%至少有一种心脏代谢疾病,38.0%发生心血管/肾脏并发症或死亡。
  • 心脏代谢疾病数量越多,心血管/肾脏并发症风险越高,≥3种者OR达3.10。
  • 南亚和黑人种族患者心血管/肾脏并发症风险高于白人。

核心结论

  • 在COVID-19住院患者中,心血管并发症或死亡影响近半数患者,南亚或黑人种族及心脏代谢多病共存者风险最高。

研究设计与样本

  • 多中心前瞻性队列研究,纳入2020年2月6日至2021年3月16日英国302家医疗机构65 624例COVID-19住院成人。
  • 采用logistic模型分析基线种族、心脏代谢疾病及多病共存(0、1、2、>2种)与院内并发症的关联。

主要发现

  • 65 624例患者中44 598例(68.0%)入院时至少有一种心脏代谢疾病,24 609例(38.0%)发生心血管/肾脏并发症或死亡。
  • 与无心脏代谢疾病相比,1、2、≥3种疾病者任何心血管/肾脏并发症的OR分别为1.46(95%CI 1.39–1.54)、2.04(95%CI 1.93–2.15)和3.10(95%CI 2.92–3.29)。
  • 全因死亡呈现相似模式。
  • 与白人相比,南亚裔(OR 1.19,95%CI 1.10–1.29)和黑人(OR 1.53,95%CI 1.37–1.72)任何心血管/肾脏并发症风险更高。

临床怎么用

  • 对COVID-19住院患者应评估心脏代谢疾病数量及种族背景,以识别心血管/肾脏并发症高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Using a large national database of people hospitalised with COVID-19, we investigated the contribution of cardio-metabolic conditions, multi-morbidity and ethnicity on the risk of in-hospital cardiovascular complications and death. METHODS: A multicentre, prospective cohort study in 302 UK healthcare facilities of adults hospitalised with COVID-19 between 6 February 2020 and 16 March 2021. Logistic models were used to explore associations between baseline patient ethnicity, cardiometabolic conditions and multimorbidity (0, 1, 2, >2 conditions), and in-hospital cardiovascular complications (heart failure, arrhythmia, cardiac ischaemia, cardiac arrest, coagulation complications, stroke), renal injury and death. RESULTS: Of 65 624 patients hospitalised with COVID-19, 44 598 (68.0%) reported at least one cardiometabolic condition on admission. Cardiovascular/renal complications or death occurred in 24 609 (38.0%) patients. Baseline cardiometabolic conditions were independently associated with increased odds of in-hospital complications and this risk increased in the presence of cardiometabolic multimorbidity. For example, compared with having no cardiometabolic conditions, 1, 2 or ≥3 conditions was associated with 1.46 (95% CI 1.39 to 1.54), 2.04 (95% CI 1.93 to 2.15) and 3.10 (95% CI 2.92 to 3.29) times higher odds of any cardiovascular/renal complication, respectively. A similar pattern was observed for all-cause death. Compared with the white group, the South Asian (OR 1.19, 95% CI 1.10 to 1.29) and black (OR 1.53 to 95% CI 1.37 to 1.72) ethnic groups had higher risk of any cardiovascular/renal complication. CONCLUSIONS: In hospitalised patients with COVID-19, cardiovascular complications or death impacts just under half of all patients, with the highest risk in those of South Asian or Black ethnicity and in patients with cardiometabolic multimorbidity.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Norris T, Razieh C, Zaccardi F, et al. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart. 2022. PMID: 34911741. doi:10.1136/heartjnl-2021-320047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。